Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 3566 |
| PDBID: | 7D4B |
| Chains: | B_A |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 3.14 |
| Reference: | 10.1136/jitc-2020-002131 |
| Antibody | |
| Antibody: | PM1003 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Tumor necrosis factor receptor superfamily member 9 (CD137) |
| Antigen mutation: | No |
| Durg Target: | Q07011 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >7D4B_B|Chain B|anti-4-1BB VHH|Lama glama (9844) QVQLVESGGGVVQPGRSLRLSCAASGSTFSIVAMGWYRQAPGKQRELVASIITGDGDTNYADSVKGRFTISRDNSKNTMYLQMNSLKPEDTAVYYCYARTGYGSSWLMGHEYDYWGQGTQVTVSSLG |
Antigen
Chain: A
Mutation: NULL
| >7D4B_A|Chain A|Tumor necrosis factor receptor superfamily member 9|Homo sapiens (9606) QDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAECDCTPGFHCLGAGCSMCEQDCKQGQELTKKGCKDCCFGTFNDQKRGICRPWTNCSLDGKSVLVNGTKERDVVCGPSPLG |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: VAL32 ALA33 MET34 GLY35 TYR37 GLN44 ARG45 LEU47 SER50 ILE51 ILE52 ASP55 ASP57 ASN59 TYR97 ARG99 GLY101 TYR102 GLY103 SER104 TYR112 ASP113 TRP115 A: THR137 ASP142 LYS144 SER145 VAL146 LEU147 VAL148 ASN149 THR151 ARG154 ASP155 VAL156 VAL157 CYS158 GLY159 PRO160 SER161 PRO162 LEU163 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
